US 12,295,934 B2
Treating iron deficiency with ferric carboxymaltose
Tobias Sidelmann Christensen, Roskilde (DK); Philip Schaffalitzky De Muckadell, Virum (DK); Lars Lykke Thomsen, Holte (DK); and Claes Christian Strom, Rungsted (DK)
Assigned to PHARMACOSMOS HOLDING A/S, Holbaek (DK)
Filed by PHARMACOSMOS HOLDING A/S, Holbaek (DK)
Filed on Sep. 21, 2023, as Appl. No. 18/370,926.
Application 18/370,926 is a division of application No. 17/187,992, filed on Mar. 1, 2021, granted, now 11,806,329.
Application 17/187,992 is a division of application No. 16/822,911, filed on Mar. 18, 2020, granted, now 11,020,369, issued on Jun. 1, 2021.
Application 16/822,911 is a division of application No. PCT/EP2019/079528, filed on Oct. 29, 2019.
Claims priority of application No. 18203223 (EP), filed on Oct. 29, 2018; and application No. 18203818 (EP), filed on Oct. 31, 2018.
Prior Publication US 2024/0058295 A1, Feb. 22, 2024
Int. Cl. A61K 31/7016 (2006.01); A61K 31/295 (2006.01); A61P 7/06 (2006.01); A61P 43/00 (2006.01)
CPC A61K 31/295 (2013.01) [A61P 7/06 (2018.01)] 60 Claims
 
1. A method of reducing severity of side effects associated with hypophosphatemia in connection with repeated treatment of iron deficiency with ferric carboxymaltose to a subject in need thereof, said method comprising,
administering a dose of ferric carboxymaltose to said subject;
determining that said subject needs a further dose of ferric carboxymaltose;
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels, and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and
administering the further dose of ferric carboxymaltose to said subject.